Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 4.99
SCMP's Cash to Debt is ranked higher than
57% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.34 vs. SCMP: 4.99 )
Ranked among companies with meaningful Cash to Debt only.
SCMP' s 10-Year Cash to Debt Range
Min: 0.86  Med: 9999.00 Max: No Debt
Current: 4.99
Equity to Asset 0.67
SCMP's Equity to Asset is ranked higher than
57% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. SCMP: 0.67 )
Ranked among companies with meaningful Equity to Asset only.
SCMP' s 10-Year Equity to Asset Range
Min: -0.21  Med: 0.53 Max: 0.82
Current: 0.67
-0.21
0.82
Interest Coverage 17.92
SCMP's Interest Coverage is ranked lower than
75% of the 389 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2854.00 vs. SCMP: 17.92 )
Ranked among companies with meaningful Interest Coverage only.
SCMP' s 10-Year Interest Coverage Range
Min: 3.55  Med: 5082.02 Max: 9999.99
Current: 17.92
3.55
9999.99
F-Score: 8
Z-Score: 15.32
M-Score: -2.27
WACC vs ROIC
18.98%
75.47%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 31.38
SCMP's Operating margin (%) is ranked higher than
93% of the 667 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.78 vs. SCMP: 31.38 )
Ranked among companies with meaningful Operating margin (%) only.
SCMP' s 10-Year Operating margin (%) Range
Min: -903.97  Med: 10.21 Max: 28.03
Current: 31.38
-903.97
28.03
Net-margin (%) 20.02
SCMP's Net-margin (%) is ranked higher than
87% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.89 vs. SCMP: 20.02 )
Ranked among companies with meaningful Net-margin (%) only.
SCMP' s 10-Year Net-margin (%) Range
Min: -906.55  Med: 5.93 Max: 41.39
Current: 20.02
-906.55
41.39
ROE (%) 31.53
SCMP's ROE (%) is ranked higher than
90% of the 696 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. SCMP: 31.53 )
Ranked among companies with meaningful ROE (%) only.
SCMP' s 10-Year ROE (%) Range
Min: -130.02  Med: 12.81 Max: 154.11
Current: 31.53
-130.02
154.11
ROA (%) 18.11
SCMP's ROA (%) is ranked higher than
89% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.32 vs. SCMP: 18.11 )
Ranked among companies with meaningful ROA (%) only.
SCMP' s 10-Year ROA (%) Range
Min: -83.83  Med: 3.14 Max: 37.89
Current: 18.11
-83.83
37.89
ROC (Joel Greenblatt) (%) 241.36
SCMP's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.13 vs. SCMP: 241.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SCMP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -19383.08  Med: 135.84 Max: 6536.15
Current: 241.36
-19383.08
6536.15
Revenue Growth (3Y)(%) 25.50
SCMP's Revenue Growth (3Y)(%) is ranked higher than
87% of the 546 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. SCMP: 25.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SCMP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -21.1  Med: 19.00 Max: 127
Current: 25.5
-21.1
127
» SCMP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

SCMP Guru Trades in Q3 2014

Paul Tudor Jones 12,761 sh (New)
» More
Q4 2014

SCMP Guru Trades in Q4 2014

Jim Simons 58,800 sh (New)
Paul Tudor Jones 12,561 sh (-1.57%)
» More
Q1 2015

SCMP Guru Trades in Q1 2015

Joel Greenblatt 103,538 sh (New)
Jim Simons 223,714 sh (+280.47%)
Paul Tudor Jones 13,209 sh (+5.16%)
» More
Q2 2015

SCMP Guru Trades in Q2 2015

Joel Greenblatt 334,346 sh (+222.92%)
Jim Simons 334,100 sh (+49.34%)
Paul Tudor Jones 15,209 sh (+15.14%)
» More
» Details

Insider Trades

Latest Guru Trades with SCMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 49.00
SCMP's P/E(ttm) is ranked lower than
63% of the 479 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.40 vs. SCMP: 49.00 )
Ranked among companies with meaningful P/E(ttm) only.
SCMP' s 10-Year P/E(ttm) Range
Min: 5.44  Med: 27.43 Max: 115.73
Current: 49
5.44
115.73
Forward P/E 28.01
SCMP's Forward P/E is ranked lower than
54% of the 232 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.58 vs. SCMP: 28.01 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 43.40
SCMP's PE(NRI) is ranked lower than
62% of the 477 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.40 vs. SCMP: 43.40 )
Ranked among companies with meaningful PE(NRI) only.
SCMP' s 10-Year PE(NRI) Range
Min: 5.42  Med: 27.12 Max: 118.63
Current: 43.4
5.42
118.63
P/B 11.82
SCMP's P/B is ranked lower than
90% of the 644 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.12 vs. SCMP: 11.82 )
Ranked among companies with meaningful P/B only.
SCMP' s 10-Year P/B Range
Min: 0.97  Med: 4.63 Max: 11.82
Current: 11.82
0.97
11.82
P/S 9.68
SCMP's P/S is ranked lower than
77% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.13 vs. SCMP: 9.68 )
Ranked among companies with meaningful P/S only.
SCMP' s 10-Year P/S Range
Min: 1.2  Med: 3.13 Max: 9.68
Current: 9.68
1.2
9.68
PFCF 31.41
SCMP's PFCF is ranked higher than
66% of the 267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 42.27 vs. SCMP: 31.41 )
Ranked among companies with meaningful PFCF only.
SCMP' s 10-Year PFCF Range
Min: 3.68  Med: 29.71 Max: 346.4
Current: 31.41
3.68
346.4
POCF 31.41
SCMP's POCF is ranked lower than
51% of the 387 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.20 vs. SCMP: 31.41 )
Ranked among companies with meaningful POCF only.
SCMP' s 10-Year POCF Range
Min: 3.64  Med: 28.75 Max: 158.17
Current: 31.41
3.64
158.17
EV-to-EBIT 26.16
SCMP's EV-to-EBIT is ranked higher than
53% of the 488 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.19 vs. SCMP: 26.16 )
Ranked among companies with meaningful EV-to-EBIT only.
SCMP' s 10-Year EV-to-EBIT Range
Min: -1008.9  Med: 5.70 Max: 66.7
Current: 26.16
-1008.9
66.7
Shiller P/E 261.84
SCMP's Shiller P/E is ranked lower than
97% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.90 vs. SCMP: 261.84 )
Ranked among companies with meaningful Shiller P/E only.
SCMP' s 10-Year Shiller P/E Range
Min: 4.62  Med: 50.46 Max: 512.67
Current: 261.84
4.62
512.67
Current Ratio 4.16
SCMP's Current Ratio is ranked higher than
73% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. SCMP: 4.16 )
Ranked among companies with meaningful Current Ratio only.
SCMP' s 10-Year Current Ratio Range
Min: 1.27  Med: 3.60 Max: 9.21
Current: 4.16
1.27
9.21
Quick Ratio 4.15
SCMP's Quick Ratio is ranked higher than
77% of the 617 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. SCMP: 4.15 )
Ranked among companies with meaningful Quick Ratio only.
SCMP' s 10-Year Quick Ratio Range
Min: 1.27  Med: 3.60 Max: 9.21
Current: 4.15
1.27
9.21
Days Inventory 3.88
SCMP's Days Inventory is ranked higher than
98% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 112.66 vs. SCMP: 3.88 )
Ranked among companies with meaningful Days Inventory only.
SCMP' s 10-Year Days Inventory Range
Min: 2.34  Med: 2.71 Max: 3.08
Current: 3.88
2.34
3.08
Days Sales Outstanding 22.41
SCMP's Days Sales Outstanding is ranked higher than
88% of the 598 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.39 vs. SCMP: 22.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
SCMP' s 10-Year Days Sales Outstanding Range
Min: 1.75  Med: 10.65 Max: 30.77
Current: 22.41
1.75
30.77

Valuation & Return

vs
industry
vs
history
Price/Net Cash 22.99
SCMP's Price/Net Cash is ranked lower than
63% of the 178 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.02 vs. SCMP: 22.99 )
Ranked among companies with meaningful Price/Net Cash only.
SCMP' s 10-Year Price/Net Cash Range
Min: 1.7  Med: 5.16 Max: 19.2
Current: 22.99
1.7
19.2
Price/Net Current Asset Value 15.20
SCMP's Price/Net Current Asset Value is ranked lower than
71% of the 385 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. SCMP: 15.20 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SCMP' s 10-Year Price/Net Current Asset Value Range
Min: 1.47  Med: 6.51 Max: 32.7
Current: 15.2
1.47
32.7
Price/Tangible Book 11.83
SCMP's Price/Tangible Book is ranked lower than
82% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. SCMP: 11.83 )
Ranked among companies with meaningful Price/Tangible Book only.
SCMP' s 10-Year Price/Tangible Book Range
Min: 1.16  Med: 4.59 Max: 11.29
Current: 11.83
1.16
11.29
Price/Projected FCF 10.10
SCMP's Price/Projected FCF is ranked lower than
85% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. SCMP: 10.10 )
Ranked among companies with meaningful Price/Projected FCF only.
SCMP' s 10-Year Price/Projected FCF Range
Min: 1.02  Med: 4.03 Max: 43.13
Current: 10.1
1.02
43.13
Price/Median PS Value 3.09
SCMP's Price/Median PS Value is ranked lower than
88% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.28 vs. SCMP: 3.09 )
Ranked among companies with meaningful Price/Median PS Value only.
SCMP' s 10-Year Price/Median PS Value Range
Min: 0.69  Med: 1.04 Max: 2.55
Current: 3.09
0.69
2.55
Price/Graham Number 4.99
SCMP's Price/Graham Number is ranked lower than
77% of the 367 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.43 vs. SCMP: 4.99 )
Ranked among companies with meaningful Price/Graham Number only.
SCMP' s 10-Year Price/Graham Number Range
Min: 0.95  Med: 2.48 Max: 5.32
Current: 4.99
0.95
5.32
Earnings Yield (Greenblatt) (%) 3.81
SCMP's Earnings Yield (Greenblatt) (%) is ranked higher than
67% of the 695 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. SCMP: 3.81 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SCMP' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.5  Med: 5.20 Max: 119.5
Current: 3.81
1.5
119.5

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 141 175 221
EPS($) 0.76 1.00 1.65
EPS without NRI($) 0.76 1.00 1.65

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:R3A.Germany,
Sucampo Pharmaceuticals Inc was incorporated on 05 December 1996. The Company is a biopharmaceutical company engaged in research, discovery, development and commercialization of proprietary drugs based on ion channel activators known as prostones. The Company is engaged in developing and/or commercializing prostone-based drugs to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and also considering other potential therapeutic applications of its drug technologies. It generates revenue primarily from product royalties, development milestone payments, clinical development activities and product sales. The Company seeks additional regulatory approvals and additional indications for AMITIZA (lubiprostone), RESCULA (unoprostone isopropyl) and other compounds. Its operations are conducted through subsidiaries based in Japan, the United States, Switzerland, the United Kingdom and Luxembourg. Its reportable geographic segments are Asia, the Americas and Europe. The Company has over 525 active issued patents based on its proprietary prostone technology. It holds all commercialization rights for unoprostone isopropyl except for Japan, Korea, Taiwan and the People's Republic of China.
» More Articles for SCMP

Headlines

Articles On GuruFocus.com
NeoPhotonics Delivers Sustained Profitability; Gevo Continues Biofuel Deal Momentum May 08 2015 
Pharmaceutical Stock Picks For March Mar 04 2015 
Weekly CEO Sells Highlight: VeriFone Systems Inc, Northeast Utilities, Sucampo Pharmaceuticals Inc, Jan 26 2014 
Weekly CEO Sells Highlight: Sucampo Pharmaceuticals Inc, Family Dollar Stores Inc, Nike Inc, Hallibu Oct 21 2013 
comment on SCMP Mar 06 2013 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 08 2011 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 03 2010 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) May 10 2010 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 06 2009 

More From Other Websites
Ambarella Leads 4 Top Stocks With Rising Estimates Aug 28 2015
Stock Market Today - 08/27/2015 Aug 27 2015
Sucampo to Acquire R-Tech Ueno for About $278 Million Aug 27 2015
Why does Sucampo want to acquire its founders' Japanese company? Transformation. Aug 27 2015
Bethesda pharmaceutical makes $278 million all-cash offer for Japanese company Aug 26 2015
SUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Aug 26 2015
Sucampo Launches Tender Offer to Acquire R-Tech Ueno Aug 26 2015
6:18 am Sucampo Pharma launches a tender offer to acquire R-Tech Ueno for JPY33 billion Aug 26 2015
Sucampo Launches Tender Offer to Acquire R-Tech Ueno Aug 26 2015
Stocks Down Hard, But Off Lows; All IBD 50 Stocks Lower Aug 24 2015
Coverage initiated on Sucampo Pharma by H.C. Wainwright Aug 24 2015
5 stocks to watch Aug 19 2015
SUCAMPO PHARMACEUTICALS, INC. Financials Aug 14 2015
SUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant,... Aug 14 2015
10-Q for Sucampo Pharmaceuticals, Inc. Aug 07 2015
Sucampo's (SCMP) Q2 Earnings Rise Y/Y, 2015 View Raised - Analyst Blog Aug 06 2015
Sucampo Stock Hits High On EPS, But CVS Nixes Drug Aug 05 2015
Edited Transcript of SCMP earnings conference call or presentation 5-Aug-15 12:30pm GMT Aug 05 2015
Sucampo Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today Aug 05 2015
Sucampo Reports Second Quarter 2015 Financial Results and Corporate Update Aug 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK